The characterization of a novel V1b antagonist lead series

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 92-96

  Smethurst, Chris A ^a   Borthwick, Jennifer A ^a   Gaines, Simon ^a   Watson, Steve ^a   Green, Andrew ^a   Schulz, Mark J ^b   Burton, George ^b   Buson, Alberto A ^c   Arban, Roberto ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GSK   (Italy)

Author keywords

Anxiety; Depression; Vasopressin

Indexed keywords

NELIVAPTAN; OXYTOCIN RECEPTOR; THIAZOLE; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR;

ARTICLE; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; HIGH-THROUGHPUT SCREENING ASSAYS; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIAZOLES;

EID: 78650515160     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.061     Document Type: Article

References (16)

1. F. Ali, M. Guglin, P. Vaitkevicius, and J.K. Ghali Drugs 67 2007 847
2. M. Thibonnier Expert Opin. Investig. Drugs 7 1998 729
3. T. Steckler, F. Holsboer, and J.M. Reul Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 13 1999 597
4. M. Thibonnier, L.N. Berti-Mattera, N. Dulin, D.M. Conarty, and R. Mattera Prog. Brain Res. 119 1998 147
5. F. Spiga, L.R. Harrison, S. Wood, D.M. Knight, C.P. MacSweeney, F. Thomson, M. Craighead, and S.L. Lightman J. Endocrinol. 200 2009 273
6. A. Tanoue, K. Honda, S. Oshikawa, Y. Kitigawa, T. Koshimizu, and T. Mori J. Clin. Invest. 113 2004 302
7. S.R. Wersinger, E.I. Ginns, A.-M. O'Carroll, S.J. Lolait, and W.S. Young Mol. Psychiatry 7 2002 975
8. C. Serradeil-Le Gal, J. Wagnon, B. Tonnerre, R. Roux, G. Garcia, G. Griebel, and A. Aulombard CNS Drug Rev. 11 2005 53
9. M. Craighead, R. Milne, L. Campbell-Wan, L. Watson, J. Presland, F.J. Thomson, H.M. Marston, and C.P. MacSweeney Prog. Brain Res. 170 2008 527
10. J.D. Scott, M.W. Miller, S.W. Li, S.-I. Lin, H.A. Vaccaro, L. Hong, D.E. Mullins, M. Guzzi, J. Weinstein, R.A. Hodgson, G.B. Varty, A.W. Stamford, T.-Y. Chan, B.A. McKittrick, W.J. Greenlee, T. Priestley, and E.M. Parker Bioorg. Med. Chem. Lett. 19 2009 6018
11. H. Van de Waterbeemd, G. Camenisch, G. Folkers, J.R. Chretien, and O.A. Raevsky J. Drug Target. 6 1998 151
12. C. Griffante, A. Green, O. Curcuruto, C.P. Haslam, B.A. Dickinson, and R. Arban Br. J. Pharmacol. 146 2005 744
13. 50 values by using the Cheng and Prusoff equation.
14. Calculated using log D suite version 11. Advanced Chemistry Development, Inc., Toronto, Ontario, Canada (http://www.acdlabs.com/ ).
15. J. Yin, and S.L. Buchwald Org. Lett. 2 2000 1101
16. Pharmacokinetics measured in male Sprague-Dawley rats following intravenous (iv) and oral (po) administration. Dose was 1 mg/kg iv and 5 mg/kg po for compound 3. Dose was 1 mg/kg iv and 1 mg/kg po for all other compounds. These studies used at least three animals for each (iv/po) leg.